Sean Saint

But the upshot of this is that after they use the islet for a while,

They're all doing great.

You know, we tend to bring people to an A1C in the sevens, you know, very near goal as an average.

And this is exactly what those higher A1C people have failed to have before.

So that was our goal as a company, not to take the great control people and get them under slightly better control, but to bring, you know, the option of good control to people who've really never had it prior.

Well, carb counting or, you know, the willingness to go in and give a, you know, multiple correction boluses, et cetera.

It's interesting with diabetes, every intervention that I can think of, we've studied all of them, of course, and they all have the same upshot, which is the more you engage with that particular technology, the better you do until the islet.

And our data from Betabionics suggests that

The outcomes are largely independent of engagement.

And that's incredible, right?

It's yes, it's both the user experience improvement for those who don't want to engage.

And it's the option of a good outcome for those who, for whatever reason, aren't able to engage, which is a huge cross section of the country, unfortunately.

Yeah, absolutely.

Let me quickly take a step back and hit what I call the four questions.

These are the four things people care about when they get their insulin pump.

You know, we talk about the algorithm.

We've been talking about that for a while.

Clearly, we believe we have algorithm advantages in our products.

So you got to get that right.

Form factor, right?